drugset / Trial / NCT06864182
Relative Bioavailability Study of CX2101A for the Treatment of COVID-19
RandomizedParallel-groupDouble-blindTreatment
Summary
The study comprises three parts: single ascending dose (SAD) studies of CX2101A tablets at 40 mg, 100 mg, and 160 mg; a relative bioavailability (BA) study comparing single-dose administration of 100 mg CX2101A tablets and enteric-coated tablets; and a multiple ascending dose (MAD) study of CX2101A tablets. The BA study (100 mg) is integrated into the SAD study(Nested within the SAD protocol to optimize resource utilization).
Timeline
- Start
- 2024-03-21
- Primary completion
- 2024-05-25
- Completion
- 2024-05-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CX2101A | Unknown | 40 mg | Oral |
| Subject | CX2101A | Unknown | 100 mg | Oral |
| Subject | CX2101A | Unknown | 160 mg | Oral |
| Subject | CX2101A enteric-coated | Unknown | 100 mg | Oral |